Intestinal stricture in Crohn's disease: A 2020 update,Journal of Digestive Diseases

当前位置： X-MOL 学术 › J. Dig. Dis. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Intestinal stricture in Crohn's disease: A 2020 update
Journal of Digestive Diseases ( IF 2.3 ) Pub Date : 2021-05-20 , DOI: 10.1111/1751-2980.13022
Xiao Xuan Lin ₁ , Yun Qiu ₁ , Xiao Jun Zhuang ₁ , Fen Liu ₁ , Xiao Min Wu ₁ , Min Hu Chen ₁ , Ren Mao ₁

Affiliation

Crohn's disease (CD) is a chronic and relapsing–remitting inflammatory disorder of the gastrointestinal tract. Approximately 70% of patients inevitably develop fibrosis-associated intestinal stricture after 10 years of CD diagnosis, which seriously affects their quality of life. Current therapies play limited role in preventing or reversing the process of fibrosis and no specific anti-fibrotic therapy is yet available. Nearly half of patients thus have no alternative but to receive surgery. The potential mechanisms of intestinal fibrosis remain poorly understood; extracellular matrix remodeling, aberrant immune response, intestinal microbiome imbalance and creeping fat might exert fundamental influences on the multiple physiological and pathophysiological processes. Recently, the emerging new diagnostic techniques have markedly promoted an accurate assessment of intestinal stricture by distinguishing fibrosis from inflammation, which is crucial for guiding treatment and predicting prognosis. In this review, we concisely summarized the key studies published in the year 2020 covering pathogenesis, diagnostic modalities, and therapeutic strategy of intestinal stricture. A comprehensive and timely review of the updated researches in intestinal stricture could provide insight to further elucidate its pathogenesis and identify novel drug targets with anti-fibrotic potentiality.

中文翻译：

克罗恩病的肠狭窄：2020 年更新

克罗恩病 (CD) 是一种慢性、复发-缓解的胃肠道炎症性疾病。大约 70% 的患者在 CD 诊断 10 年后不可避免地发生纤维化相关的肠狭窄，这严重影响了他们的生活质量。目前的疗法在预防或逆转纤维化过程中的作用有限，并且尚无特定的抗纤维化疗法可用。因此，近一半的患者别无选择，只能接受手术。肠道纤维化的潜在机制仍然知之甚少。细胞外基质重塑、异常免疫反应、肠道微生物组失衡和脂肪蠕动可能对多种生理和病理生理过程产生根本性影响。最近，新兴的诊断技术通过区分纤维化和炎症，显着促进了对肠道狭窄的准确评估，这对于指导治疗和预测预后至关重要。在这篇综述中，我们简要总结了 2020 年发表的主要研究，涵盖肠狭窄的发病机制、诊断方式和治疗策略。对肠道狭窄的最新研究进行全面及时的回顾可以为进一步阐明其发病机制和确定具有抗纤维化潜力的新药物靶点提供见解。我们简要总结了 2020 年发表的主要研究，涵盖肠狭窄的发病机制、诊断方式和治疗策略。对肠道狭窄的最新研究进行全面及时的回顾可以为进一步阐明其发病机制和确定具有抗纤维化潜力的新药物靶点提供见解。我们简要总结了 2020 年发表的主要研究，涵盖肠狭窄的发病机制、诊断方式和治疗策略。对肠道狭窄的最新研究进行全面及时的回顾可以为进一步阐明其发病机制和确定具有抗纤维化潜力的新药物靶点提供见解。

更新日期：2021-07-12

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11